RedHill Biopharma (RDHL) Stock Forecast, Price & News

RedHill Biopharma's stock was trading at $5.6120 at the beginning of 2023. Since then, RDHL stock has decreased by 60.8% and is now trading at $2.20.
View the best growth stocks for 2023 here.

RedHill Biopharma saw a drop in short interest in May. As of May 15th, there was short interest totaling 116,600 shares, a drop of 31.7% from the April 30th total of 170,700 shares. Based on an average trading volume of 97,100 shares, the short-interest ratio is currently 1.2 days. Currently, 4.0% of the company's shares are short sold.
View RedHill Biopharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 22nd 2023.
View our RDHL earnings forecast.

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share for the quarter, missing analysts' consensus estimates of ($19.20) by $0.80. The biotechnology company had revenue of $21.61 million for the quarter, compared to analyst estimates of $23.41 million. During the same quarter in the previous year, the business posted ($20.00) earnings per share.

RedHill Biopharma shares reverse split on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

RedHill Biopharma updated its fourth quarter 2022 earnings guidance on Monday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.50 million-$15.50 million, compared to the consensus revenue estimate of $18.10 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

RedHill Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.61%), Acadian Asset Management LLC (0.85%), Belvedere Trading LLC (0.00%) and Simplex Trading LLC (0.00%).

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RDHL stock can currently be purchased for approximately $2.20.

RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $8.65 million and generates $61.80 million in revenue each year. The biotechnology company earns $-71,670,000.00 in net income (profit) each year or ($62.40) on an earnings per share basis.

The company employs 201 workers across the globe.

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.